table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID-19 mild to moderate
Immunosuppressants drugs
anakinra CORIMUNO-ANA-1
anti-interleukin-6
tocilizumab Capra
janus kinase (JAK) inhibitor
baricitinib Cantini Rodriguez-Garcia
tofacitinib Murugesan
lenzilumab LIVE-AIR ...

2 studies excluded by filtering options 2

5523 Toniati, 2020 2990excludednot a RCTrisk of bias not avaialble
5526 Price, 2020 2130excludednot a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons